Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-4528 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase 1a: GS-4528 Monotherapy Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of GS-4528 monotherapy to determine the maximum tolerated dose. |
| Phase 1a: GS-4528 Monotherapy Dose Expansion | EXPERIMENTAL | Participants will receive GS-4528 monotherapy at the dose determined in the escalation phase. |
| Phase 1b:Dose Escalation of GS-4528 in Combination With Anti-PD-1 Monoclonal Antibody (zimberelimab) | EXPERIMENTAL | Participants will receive escalating doses of GS-4528 in combination with anti-PD1 monoclonal antibody (zimberelimab) to determine the maximum tolerated dose of GS-4528 as a combination therapy. |
| Name | Type | Description |
|---|---|---|
| GS-4528 | BIOLOGICAL | Administered intravenously |
| Zimberelimab | DRUG | Administered intravenously. |
Key Inclusion Criteria: * Documented disease: * Phase 1a dose escalation and backfill cohorts; Phase 1b dose escalation: Individuals with histologically or cytologically confirmed advanced solid tumors who have received, been intolerant to, or been ineligible for all treatment known to confer cl...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GS-4528 is an investigational monoclonal antibody being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in adults with solid tumors to evaluate its safety and potential efficacy.
GS-4528 is a monoclonal antibody, but its specific molecular target has not been disclosed. As an antibody-based therapy, it is designed to bind to a particular antigen involved in tumor growth, though the exact target is not publicly available at this time.
GS-4528 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. Gilead is conducting clinical research on this drug for the treatment of solid tumors.
GS-4528 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary activity of the drug in patients with solid tumors.
GS-4528 is being studied in a Phase 1 clinical trial identified as NCT05840224, titled 'Study of GS-4528 in Adults With Solid Tumors.' The trial is active but not recruiting, with an enrollment of 182 participants across the United States, Canada, South Korea, Spain, Taiwan, and the United Kingdom.